Rein Therapeutics Inc.
RNTX
$1.27
$0.1412.39%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 9.96M | 12.68M | 13.86M | 16.72M | 16.33M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 24.35M | 26.52M | 28.11M | 29.62M | 25.52M |
Operating Income | -24.35M | -26.52M | -28.11M | -29.62M | -25.52M |
Income Before Tax | -60.70M | -62.82M | -64.43M | -29.24M | -25.22M |
Income Tax Expenses | -1.54M | -1.54M | -1.54M | -- | -- |
Earnings from Continuing Operations | -59.15 | -61.27 | -62.88 | -29.24 | -25.22 |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -59.15M | -61.27M | -62.88M | -29.24M | -25.22M |
EBIT | -24.35M | -26.52M | -28.11M | -29.62M | -25.52M |
EBITDA | -24.33M | -26.50M | -28.05M | -29.50M | -25.40M |
EPS Basic | -2.69 | -2.86 | -3.46 | -3.11 | -3.25 |
Normalized Basic EPS | -0.66 | -0.77 | -1.14 | -1.95 | -2.03 |
EPS Diluted | -2.69 | -2.86 | -3.46 | -3.11 | -3.25 |
Normalized Diluted EPS | -0.66 | -0.77 | -1.14 | -1.95 | -2.03 |
Average Basic Shares Outstanding | 89.46M | 85.18M | 71.57M | 54.65M | 37.52M |
Average Diluted Shares Outstanding | 89.46M | 85.18M | 71.57M | 54.65M | 37.52M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |